PMID- 30171723
OWN - NLM
STAT- MEDLINE
DCOM- 20191202
LR  - 20200204
IS  - 1097-4644 (Electronic)
IS  - 0730-2312 (Linking)
VI  - 119
IP  - 12
DP  - 2018 Dec
TI  - Comparison between the effect of human Wharton's jelly-derived mesenchymal stem 
      cells and levetiracetam on brain infarcts in rats.
PG  - 9790-9800
LID - 10.1002/jcb.27297 [doi]
AB  - BACKGROUND: Stroke represents one of the major causes of death worldwide. 
      Neuroprotection remains an important goal of stroke therapy. Stem cell 
      therapeutic effect is attributed to the neuroprotective effect and the regulation 
      of the oxidant stress. Levetiracetam (LEV), a second-generation antiepileptic 
      drug, was reported to confer neuronal protection after cerebral ischemia 
      reperfusion. AIM: To investigate the effect of human Wharton's jelly-derived 
      mesenchymal stem cells (WJ-MSCs) and LEV on the size of brain infarcts, the 
      histological structure, the neurotrophic, and the antioxidant gene expression in 
      middle cerebral artery occlusion in rats. METHOD: The rats were divided into five 
      equal groups of 12 rats each as follows. Sham control group: received 
      phosphate-buffered saline (PBS); ischemia/reperfusion (I/R) group: received PBS 
      before ligation; stem cell-treated group: the animal received MSCs before 
      ligation; LEV-treated group: the animal received LEV before occlusion; combined 
      group: the animals received both MSCs and LEV before occlusion. Hematoxylin and 
      eosin staining was performed to study the histological structure of the brain. 
      Real-time polymerase chain reaction (RT-PCR) was performed to assess gene 
      expression. RESULTS: Both MSCs and LEV improved memory and learning in the 
      treated groups compared with I/R group. Significant reduction of the infarct size 
      in WJ-MSC- or LEV-treated groups when compared with untreated ones was found. By 
      RT-PCR, a significant decrease of the expression values of glial-derived 
      neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), 
      phosphatidylethanolamine binding protein 1 (PEBP1), and copper-zinc SOD 
      (Cu/ZnSOD) genes and a significant increase of pro-oxidant iNOS gene in the I/R 
      rats compared with the sham group was detected. There was a significant increase 
      in the expression values of GDNF, BDNF, PEBP1, and Cu/ZnSOD genes in both treated 
      groups when compared with the I/R group. Rats treated with WJ-MSCs showed better 
      results than rats treated with LEV. Finally, the combined use of LEV and WJ-MSCs 
      was the most effective regimen as regard infarction volume and functional 
      learning and memory tests. CONCLUSION: In the brain ischemia model, combined 
      WJ-MSCs and LEV have demonstrated striking protective effects in brain infarction 
      by the modulation of the oxidant status and neuroprotective effect.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Abd El Motteleb, Dalia M
AU  - Abd El Motteleb DM
AD  - Pharmacology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
FAU - Hussein, Samia
AU  - Hussein S
AUID- ORCID: 0000-0002-7407-1608
AD  - Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, 
      Zagazig University, Zagazig, Egypt.
FAU - Hasan, Mai M
AU  - Hasan MM
AD  - Medical Physiology Department, Faculty of Medicine, Zagazig University, Zagazig, 
      Egypt.
FAU - Mosaad, Hala
AU  - Mosaad H
AD  - Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, 
      Zagazig University, Zagazig, Egypt.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20180901
PL  - United States
TA  - J Cell Biochem
JT  - Journal of cellular biochemistry
JID - 8205768
RN  - 0 (Bdnf protein, rat)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (GFAP protein, rat)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor)
RN  - 0 (Glial Fibrillary Acidic Protein)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (PEBP1 protein, rat)
RN  - 0 (Phosphatidylethanolamine Binding Protein)
RN  - 44YRR34555 (Levetiracetam)
RN  - EC 3.4.22.- (Casp3 protein, rat)
RN  - EC 3.4.22.- (Caspase 3)
SB  - IM
MH  - Animals
MH  - Brain Infarction/metabolism/pathology/*therapy
MH  - Brain-Derived Neurotrophic Factor/genetics
MH  - Caspase 3/metabolism
MH  - Gene Expression
MH  - Glial Cell Line-Derived Neurotrophic Factor/genetics
MH  - Glial Fibrillary Acidic Protein/metabolism
MH  - Humans
MH  - Learning/drug effects/physiology
MH  - Levetiracetam/*pharmacology
MH  - Male
MH  - Memory/drug effects/physiology
MH  - Mesenchymal Stem Cell Transplantation/*methods
MH  - Neuroprotective Agents/*pharmacology
MH  - Phosphatidylethanolamine Binding Protein/genetics
MH  - Rats
MH  - Wharton Jelly/*cytology
OTO - NOTNLM
OT  - Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs)
OT  - brain infarction
OT  - levetiracetam (LEV)
OT  - middle cerebral artery occlusion (MCAO)
OT  - real-time polymerase chain reaction (RT-PCR)
EDAT- 2018/09/02 06:00
MHDA- 2019/12/04 06:00
CRDT- 2018/09/02 06:00
PHST- 2017/11/23 00:00 [received]
PHST- 2018/06/26 00:00 [accepted]
PHST- 2018/09/02 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2018/09/02 06:00 [entrez]
AID - 10.1002/jcb.27297 [doi]
PST - ppublish
SO  - J Cell Biochem. 2018 Dec;119(12):9790-9800. doi: 10.1002/jcb.27297. Epub 2018 Sep 
      1.